GlassScriptPhysician profile
Rebecca Thrun
NPI 1891131223
$3,672.80
in general payments reported to CMS, 2019-2025
34 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $251 · 2021: $161 · 2022: $231 · 2023: $436 · 2024: $529 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.05 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $342.76 | 2019-2020 | |
| Pfizer INC. | $309.82 | 2019-2025 | |
| Abbott Laboratories | $234.97 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.91 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $212.70 | 2019-2024 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $166.19 | 2019-2025 | Capvaxive |
| Glaxosmithkline, LLC. | $161.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teleflex LLC | $148.62 | 2025 | Urolift |
| Insulet Corporation | $138.66 | 2024 | Omnipod |
| Novo Nordisk INC | $126.37 | 2019-2024 | Wegovy |
| Amgen INC. | $115.25 | 2019-2025 | Otezla, Repatha |
| Lilly USA, LLC | $114.24 | 2019 | |
| Amarin Pharma, INC. | $97.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.95 | 2019-2024 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $83.91 | 2019-2022 | |
| Exact Sciences Corporation | $83.62 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $63.49 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $55.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.03 | 2019-2024 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $41.85 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $36.42 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $35.63 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $33.15 | 2023 | Inpefa |
| Axsome Therapeutics, INC. | $31.08 | 2024 | Auvelity |
| Allergan, INC. | $29.92 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.22 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.14 | 2025 | Fanapt |
| Currax Pharmaceuticals LLC | $14.37 | 2020 | |
| Zyla Life Sciences, INC. | $14.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.78 | 2019 | |
| Hologic Sales and Service, LLC | $12.32 | 2019 | |
| Genentech USA, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Thrun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.